KDIGO 2022 CKD Diabetes Guideline
The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (PMID 36272755, Kidney Int 2022) provides the most widely referenced international framework for managing T2D in patients with CKD. The guideline establishes a three-tier hierarchy for glucose-lowering therapy in T2D+CKD that is critically important for positioning tirzepatide in this population.
Treatment hierarchy (Figure 23, KDIGO 2022):
- Metformin (Grade 1B): First-line if eGFR ≥30 ml/min/1.73m². Stop if eGFR falls below 30.
- SGLT2 inhibitor (Grade 1A — strongest recommendation): Add to metformin if eGFR ≥20 ml/min/1.73m²; continue as tolerated until dialysis or transplantation even as eGFR declines below the glucose-lowering threshold. This is the only glucose-lowering drug class with dedicated large powered trials showing kidney outcomes benefit: CREDENCE (canagliflozin), DAPA-CKD (dapagliflozin), EMPA-KIDNEY (empagliflozin).
- GLP-1 receptor agonist (Grade 1B): Add when individualised glycaemic targets are not met despite metformin + SGLT2i, or when those agents cannot be used. GLP-1 RAs are “generally preferred” over DPP-4 inhibitors, TZDs, and sulfonylureas as the third-tier agent.
Tirzepatide’s position under KDIGO 2022: Tirzepatide is not specifically named in the guideline — it was approved by the FDA in May 2022, concurrent with guideline finalization. However, it falls squarely within the GLP-1 RA class recommendation (Grade 1B). Given its superior glycaemic and weight-reduction efficacy vs semaglutide (SURPASS-2) and the kidney-protective post-hoc data from SURPASS-4 (PMID 36152639 — eGFR preserved, UACR reduced), tirzepatide is a reasonable GLP-1 RA choice under the KDIGO framework. However, it lacks a dedicated powered kidney outcomes trial (unlike SGLT2 inhibitors or the semaglutide FLOW trial), and KDIGO would place it in third-line position after both metformin and SGLT2i.
Practical implications for the vault’s target patient: A T2D patient aged 50+ with CKD and long diabetes duration would ideally be on:
- Metformin (if eGFR ≥30)
- SGLT2i (if eGFR ≥20) — for kidney and CV protection
- Tirzepatide or other GLP-1 RA — if HbA1c remains inadequate on metformin + SGLT2i
In patients with advanced CKD (eGFR <20) where SGLT2i are initiated but may be insufficient, or in patients intolerant of SGLT2i, tirzepatide (as a GLP-1 RA) would be the next preferred agent per KDIGO. However, in patients with eGFR <30 where both metformin and tirzepatide’s full use may need caution (not a safety contraindication, but prescribing care needed), the treatment hierarchy becomes more complex.
Ontology KDIGO 2022 CKD Diabetes Guideline [guideline_for] Tirzepatide KDIGO 2022 CKD Diabetes Guideline [guideline_for] Type 2 Diabetes KDIGO 2022 CKD Diabetes Guideline [relates] Kidney Outcomes KDIGO 2022 CKD Diabetes Guideline [relates] Dedicated CKD Outcome Trial KDIGO 2022 CKD Diabetes Guideline [relates] SGLT2 Inhibitors
Recommendations Summary
| Line | Drug | Grade | eGFR threshold | Evidence base |
|---|---|---|---|---|
| 1st | Metformin | 1B | ≥30 ml/min/1.73m² | UKPDS, general T2D evidence |
| 2nd | SGLT2 inhibitor | 1A | ≥20 ml/min/1.73m² (continue until dialysis) | CREDENCE, DAPA-CKD, EMPA-KIDNEY |
| 3rd | GLP-1 RA (incl. tirzepatide) | 1B | No eGFR cutoff specified; use with clinical judgement | LEADER, REWIND, SUSTAIN-6 (CV trials); kidney post-hoc data |
| 4th | DPP-4i, TZD, SU, insulin | Variable | Agent-specific | General T2D evidence |
Practical Interpretation for Tirzepatide
- KDIGO position: Third-line in T2D+CKD (after metformin + SGLT2i); fills the GLP-1 RA niche
- Advantage over semaglutide (in this context): superior HbA1c and weight reduction; kidney post-hoc data suggestive
- Limitation vs SGLT2i: no dedicated powered kidney outcomes trial; SGLT2i benefit is class-level and proven
- Clinical scenario where tirzepatide is preferred over SGLT2i: patient intolerant of SGLT2i, or who needs greater glycaemic control than SGLT2i alone provides, or who wants weight loss
- Open question: whether tirzepatide will eventually have a dedicated CKD outcomes trial (SURPASS-KIDNEY or similar)
Connections
- Tirzepatide — positioned within GLP-1 RA class (3rd line per KDIGO 2022)
- Kidney Outcomes — guideline context
- Dedicated CKD Outcome Trial — evidence_gap_for (tirzepatide lacks this; SGLT2i have it)
- SGLT2 Inhibitors — higher-priority per KDIGO for T2D+CKD
- ADA Standards of Care 2023-2024 — relates (ADA also prioritises SGLT2i+GLP-1 RA for CKD)